EtoposideInfusions, IntravenousInfusions, ParenteralInfusion PumpsAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsInfusions, Intra-ArterialTopoisomerase II InhibitorsCisplatinIfosfamideCarcinoma, Small CellDrug Administration ScheduleDNA Topoisomerases, Type IIPodophyllotoxinDoxorubicinVincristineCyclophosphamideCarboplatinAmsacrineDose-Response Relationship, DrugCombined Modality TherapyAntineoplastic AgentsBleomycinLung NeoplasmsCytarabineTreatment OutcomeInfusion Pumps, ImplantableGerminomaDrug EvaluationLeukopeniaTeniposideTransplantation, AutologousRemission InductionAdministration, OralTime FactorsInfusions, SubcutaneousNucleic Acid Synthesis InhibitorsTopoisomerase InhibitorsDrug Resistance, NeoplasmMitoxantroneCamptothecinApoptosisTesticular NeoplasmsHematologic DiseasesNeutropeniaNeoplasms, Germ Cell and EmbryonalInjections, IntravenousTopotecanSalvage TherapyThrombocytopeniaSurvival AnalysisHodgkin DiseaseDisease-Free SurvivalLymphoma, Non-HodgkinPaclitaxelSurvival RateCarmustineDNA DamageInfusions, IntralesionalTopoisomerase I InhibitorsBlood PressureTumor Cells, CulturedDrug ResistanceNeoplasmsDogsPrednisoneRazoxaneOrganophosphorus CompoundsMelphalanMetabolic Clearance RateHalf-LifeDrug Resistance, MultipleVinblastineP-GlycoproteinHematopoietic Stem Cell TransplantationProcarbazineGranulocyte Colony-Stimulating FactorMethotrexateDrug SynergismHemodynamicsBone Marrow TransplantationCell SurvivalAlopeciaInsulin Infusion SystemsRats, Sprague-DawleyInfusions, IntraventricularDrug InteractionsRecurrenceBone Marrow DiseasesDaunorubicinInsulinRetroperitoneal NeoplasmsEnzyme InhibitorsMesnaLeukemiaBlood GlucoseHeart RateHome Infusion TherapyCell Line, TumorGlucose